|
|
|
| home > ebr > Autumn 2017 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR Editor Dr Deborah O’Neil talks us through the latest innovative breakthroughs in drug discovery and explores the themes and issues covered by each of our contributors.
|
|
|
|
Assay Platform Selection
Harnessing Hybrids
ARCINOVA’s Michael Blackburn asks firms to continually question what specifically is being measured and how data quality can be ensured when using hybrid liquid chromatography-mass spectrometry assays for peptides.
 |
|
|
Method Development
Definitive Screening Designs
Dr Srividya Suryanarayana at Cytovance Biologics discusses a recent case study that used a definitive screening design for imaged capillary isoelectric focusing method optimisation, thus gaining high-quality data.
|
|
|
Regulatory Mycoplasma Testing
Rapid Methods
Nucleic acid amplification techniques are becoming the preferred option for rapid mycoplasma detection, say Professor Renate Rosengarten, Dr Carl-Ulrich Zimmerman and Dr Martina Sauert at Mycoplasma Biosafety Services.
|
|
|
|
Basal-Like Breast Cancer
Signal Detection
Dr Partha S Ray and Dr Roberto Fagnani at 3N Diagnostics introduce a new biomarker for a basal-like breast cancer, an elusive disease type previously difficult to discover and diagnose at an early stage.
|
|
|
DNA Damage and Immune Response
Firing Up
Dr Eileen Parkes at Queen’s University Belfast and Dr Nuala McCabe and Professor Richard Kennedy at Almac Diagnostics highlight the relationship between cancer cell behaviour and DNAdamage activated immune response.
|
|
|
Transgene Expression
Size Matters
PlasmidFactory’s Tatjana Buchholz, Dr Marco Schmeer and Dr Martin Schleef suggest that using minicircle DNA for transgene expression can help smooth the process by enabling improved nuclear entry.
|
|
|
Robotic Surgery
Homing In
Gaining ground in treatments for prostate cancer, thereby improving clinical outcomes and cost-efficiency, could cement robotic surgery as an established and valuable therapeutic method, says Dr Andre Faure at Trod Medical.
|
|
|
|
Precision Medicines
New Strategy
David Bunton at ReproCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia stress that early identification of genetic factors that influence efficacy in patient subpopulations is key to success.
|
|
|
Considerations for Automation
Avoiding Data Overload
Peak Analysis and Automation’s Rob Harkness uses a case study to highlight how promptly integrating automation with a flexible data handling package has a positive effect on workflow, raising the yield of high-quality data.
|
|
|
|
In Brief
Risk Ratio
Following the recent FDA approval of a cancer immunotherapy drug, Emile Bellott explores the utilisation and successes of CAR-T, nodding to the limitations that still plague such therapeutics.
|
|
|
Industry Trends
Adapt to Survive
Peter Muller at Schlafender Hase provides an overview of five trends that have dominated the life sciences industry over 2017, encouraging pharma firms to embrace change and inevitable adaptations.
|
|
|
Patents for Stem Cell Therapies
A Fresh Look
Helen Henderson and Dr Nicholas Jones at Withers & Rogers get to grips with a regulatory update from the European Patent Office that could benefit organisations currently involved in early stage stem cell research.
|
|
|
Special Feature: GDPR
EU Impact
Jon Weisberg at SAFE-BioPharma Association, Industry Advisor to EBR, gathered expert views on the potential effects of the EU General Data Protection Regulation, which goes live in spring 2018.
|
|
|
Boosting Cellular Therapies
Enhanced Effects
Dr Christian van den Bos at Mares Ltd offers a new technique to enhance cellular viability, which involves co-application of small molecules that are known to improve survival of cells post-injection.
|
|
|
Safety Testing
Revamping Regulations
NDA Group’s Dr Paula Salmikangas argues that the safety information currently required for the clinical development of stem cell products is unclear and may require serious review to improve access to innovative therapies.
|
|
|
Predicting P450 Metabolism
Driving Discovery
As well as outlining the state-of-the-art of computational approaches for predicting P450 metabolism, Matthew Segall at Optibrium Ltd identifies areas for future development.
|
|
|
The Future of Organoids
Unleashing 3D
For Dr Colin Sanctuary at QGel, the breakthrough innovation of synthetically specialised extracellular matrixes will transform the use of organoids as a model for human disease and unlock unique possibilities for personalised medicine.
|
|
|
Discovering New Medicines
Invaluable Influences
Collaboration between CROs and biotechnology firms is crucial for the discovery of new drugs, but Dr Richard Weaver FRSC at XenoGesis Ltd suggests success will also depend on the influence of drug metabolism and pharmacokinetics.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Volga-Dnepr Group Strengthens its Global Healthcare Team
Volga-Dnepr Group, the group of international air cargo carriers
with 30+ years of profound expertise in transporting various types of
cargo, has strengthened its Global Healthcare Team to support its
customers worldwide with comprehensive logistics solutions for their
pharmaceutical products.
The team will be
led by Yulia Celetaria, Healthcare Director who will be in charge of
smooth operations of the Group, alignment of dedicated healthcare and
life-saving services with the usage of the Group’s unique freighter
fleet, network connections through scheduled flights and charter
options. While previously working for AirBridgeCargo Airlines, where she
started her professional journey back in 2005, Yulia has been able to
upscale her knowledge, expertise and gain the right experience necessary
to meet the 2020 logistics challenge of the whole pharmaceutical
industry.
More info >> |
|
 |
White Papers |
 |
|
The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing
GE Healthcare Life Sciences
For the past several years, the biopharma industry has been buffeted by
dynamic market conditions that are rapidly reshaping manufacturing
requirements. These factors include:
• The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model
• Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint
• The emergence of biosimilars and continued evolution of healthcare
reform, which will increasingly pressure drug pricing and require
greater cost discipline
• Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures
• Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
.jpg)
